CTRI/2020/06/026189尚未招募2 期
Randomized, Double Blind, Parallel Group Study of Vitamin D3 & Magnesium in Covid 19 Infection - Covid
Suraksha Pharma Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients of either sex, 20 to 60 years of age with mild â?? moderate COVID -19 infection , found positive for COVID -19 test by RT_PCR are requiring Clinical management
- •( symptomatic patients who present with cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, insomnia, ageusia or alternative signs of respiratory infections.)
- •2.Participants who are willing to provide inform consent and willing to come for schedule follow up visit.
- •3.Participants who are having normal hematological renal hepatic Parameters
- •4.Participant not having contra indication to take standard treatment Vitamin D, magnesium
- •5.Participants tested positive for COVID 19 by nose throat swab using PCR technique
- •6.Signed informed consent, demonstrating that the subject understands the procedures required for the study and the purpose of the study.
排除标准
- •1.Patient having severe COVID -19 infection
- •2.Patients presenting severe respiratory and/or multi systemic symptoms compatible with advanced COVID-19 and inter current acute or severe chronic diseases (i.e. active cancer).
- •3.Participants with hypersensitivity or intolerance or contraindication to the use of standard treatment
- •4.Participants with known allergy or contraindication to Vitamin D, Magnesium
- •5.History of having received any investigational drug in the preceding one month.
- •6.History of taking any kind of formulation or any other form of therapy for COVID 19 prophylaxis .
- •7.Unwilling to come for regular follow-up for the entire duration of the study.
- •8. COVID -19 RT-PCR Negative
- •9.Any condition that, in the opinion of the investigator, does not justify the subjectâ??s inclusion in the study.
- •10.Participants participating in other clinical study.
- •11.Participant receiving other immune enhancers.
- •12.Refusal to sign informed consent form
- •13.Symptomatic for sever COVID-19 infection needing ICU
- •14.Atherosclerotic Coronary Artery Disease
研究者
相似试验
进行中（未招募）
3 期
A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft OperationTiCAB– Ticagrelor in CABGMedDRA - Cardiovascular Diseases [C14], 14.1 100000004866 10003601 Atherosclerosis LLTI20-I25Ischaemic heart diseasesDRKS00004917Klinik für Herz- und KreislauferkrankungenDeutsches Herzzentrum MünchenKlinik an der Technischen Universität München1,893
进行中（未招募）
1 期
A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft OperationTiCAB– Ticagrelor in CABGTicagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft OperationMedDRA version: 20.0Level: LLTClassification code 10003601Term: AtherosclerosisSystem Organ Class: 100000004866EUCTR2012-003630-16-DEGerman Heart Centre Munich, Department of3,850
进行中（未招募）
1 期
A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft OperationTiCAB– Ticagrelor in CABGTicagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft OperationMedDRA version: 19.0Level: LLTClassification code 10003601Term: AtherosclerosisSystem Organ Class: 100000004866EUCTR2012-003630-16-ATGerman Heart Centre Munich, Department of3,850
进行中（未招募）
不适用
Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, each in fixed dose combination with 5µg Tiotropium Bromide (Delivered by the Respimat® Inhaler) compared with 5µg Tiotropium Bromide Monoproduct (Delivered by the Respimat® Inhaler) in Patients with COPD - Efficacy and Safety of 4 Weeks Once Daily Orally Inhaled fixed dose combination BI 1744/TiotropiumChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2007-005087-26-DEBoehringer Ingelheim GmbH & Co. KG130
已完成
不适用
A Randomized, Double-blind, Parallel Group Study of the Safety and Effect on Clinical Outcome of Tocilizumab SC Versus Tocilizumab IV, in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Active Rheumatoid Arthritis-M05M05PER-083-10F. HOFFMANN-LA ROCHE LTD.,24